<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36820549</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review.</ArticleTitle><Pagination><StartPage>e32949</StartPage><MedlinePgn>e32949</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e32949</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000032949</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Eltrombopag, a thrombopoietin receptor (TPO-R) agonist, is considered a second-line treatment for patients with refractory immune thrombocytopenia (ITP). Systemic lupus erythematosus (SLE) is frequently associated with ITP. In some cases, thrombocytopenia in SLE patients is attributed to concurrent antiphospholipid antibodies (APLA). Currently, data regarding treatment with TPO-R agonists for ITP in SLE or APLA patients are limited. The incidence of SLE flare or antiphospholipid syndrome while on TPO-R agonists has not been well-studied.</AbstractText><AbstractText Label="CASES" NlmCategory="METHODS">We report 2 cases of female patients with SLE and concurrent triple positive APLA, without thrombotic events in their medical history, in our rheumatology clinic, who were treated for refractory ITP with eltrombopag. Both developed catastrophic antiphospholipid syndrome a few weeks after beginning treatment with eltrombopag. They were admitted to the intensive care unit and treated with solumedrol, plasmapheresis, anticoagulation and rituximab.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We describe a severe possible side-effect of eltrombopag as a trigger of catastrophic antiphospholipid syndrome, a rare initial manifestation of antiphospholipid syndrome, in SLE patients with APLA. We suggest that APLA should be tested before initiating eltrombopag in patients with SLE-associated ITP. The safety of this treatment should be considered in these cases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garra</LastName><ForeName>Wakar</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-6363-5981</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine E, Meir Medical Center, Kfar Saba, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmi</LastName><ForeName>Or</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine E, Meir Medical Center, Kfar Saba, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivity</LastName><ForeName>Shaye</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Yair</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine E, Meir Medical Center, Kfar Saba, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S56D65XJ9G</RegistryNumber><NameOfSubstance UI="C520809">eltrombopag</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001565">Benzoates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006834">Hydrazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001565" MajorTopicYN="N">Benzoates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006834" MajorTopicYN="N">Hydrazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>10</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36820549</ArticleId><ArticleId IdType="pmc">PMC9907943</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000032949</ArticleId><ArticleId IdType="pii">00005792-202302100-00019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Klein A, Molad Y. Hematological manifestations among patients with rheumatic diseases. Acta Haematol. 2021;144:403&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">33221805</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashal F. Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J. 2013;7:87&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816272</ArticleId><ArticleId IdType="pubmed">24198852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lusa A, Carlson A. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series. Lupus. 2018;27:1723&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29673280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanima W, Gernsheimer T, Kuter DJ. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood. 2021;137:2736&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">33827138</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-L&#xf3;pez TJ, Alvarez-Rom&#xe1;n MT, Pascual C, et al. . Use of eltrombopag for secondary immune thrombocytopenia in clinical practice. Br J Haematol. 2017;178:959&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">28573819</ArticleId></ArticleIdList></Reference><Reference><Citation>Guitton Z, Terriou L, Lega JC, et al. . Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology (Oxford). 2018;57:1432&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29757439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dai M, Fu Q, et al. . Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease. Sci Rep. 2021;11:5459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7943759</ArticleId><ArticleId IdType="pubmed">33750817</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnano L, Enr&#xed;quez H, Esteve J, et al. . Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus. J Rheumatol. 2014;41:1895&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25179983</ArticleId></ArticleIdList></Reference><Reference><Citation>Gernsheimer TB, George JN, Aledort LM, et al. . Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010;8:1372&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">20230419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shobha V, Sanil S, Roongta R. Eltrombopag: efficacy and safety in steroid refractory lupus-associated immune thrombocytopenia. J Clin Rheumatol. 2020;26:274&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31166214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-L&#xf3;pez TJ, S&#xe1;nchez-Gonz&#xe1;lez B, Jarque I, et al. . Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia. Eur J Haematol. 2020;104:259&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">31840311</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomov S, Lazarchick J, Self SE, et al. . Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim. Lupus. 2013;22:504&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23554039</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMoreaux B, Barbar-Smiley F, Ardoin S, et al. . Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist. Semin Arthritis Rheum. 2016;45:e10&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">26329147</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulon C, Vircoulon M, Constans J. Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events. Lupus. 2016;25:331.</Citation><ArticleIdList><ArticleId IdType="pubmed">26405023</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMoreaux B, Barbar-smiley F, Ardoin S, et al. . Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostin, a thrombopoietin receptor agonist. Semin Arthritis Rheum. 2015. S0049&#x2013;0172(15)00196-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">26329147</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. . 2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:1400&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreede AP, Bockenstedt PL, McCune WJ, et al. . Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. Curr Opin Rheumatol. 2019;31:231&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6455093</ArticleId><ArticleId IdType="pubmed">30747734</ArticleId></ArticleIdList></Reference><Reference><Citation>Maimoonah R, Tawfiq Soliman A, Yassin MA. Thrombosis in patients with immune thrombocytopenia, review of literature. Blood. 2020;136:9&#x2013;10.</Citation></Reference><Reference><Citation>Sun H, Tsai Y, Nowak I, et al. . Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412938</ArticleId><ArticleId IdType="pubmed">22683680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>